21543735

Source:http://linkedlifedata.com/resource/pubmed/id/21543735

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0026769, umls-concept:C0035647, umls-concept:C0087111, umls-concept:C1172734, umls-concept:C1512900
pubmed:issue	22
pubmed:dateCreated	2011-5-31
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/21543735-21543733
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0401060
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/natalizumab
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	1526-632X
pubmed:author	pubmed-author:BourdetteDennisD, pubmed-author:NaismithRobert TRT
pubmed:issnType	Electronic
pubmed:day	31
pubmed:volume	76
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1854-5
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:21543735-Antibodies, Monoclonal, pubmed-meshheading:21543735-Antibodies, Monoclonal, Humanized, pubmed-meshheading:21543735-Humans, pubmed-meshheading:21543735-Leukoencephalopathy, Progressive Multifocal, pubmed-meshheading:21543735-Multiple Sclerosis, Relapsing-Remitting, pubmed-meshheading:21543735-Recurrence, pubmed-meshheading:21543735-Risk Factors
pubmed:year	2011
pubmed:articleTitle	Interruption of natalizumab therapy for multiple sclerosis: what are the risks?
pubmed:publicationType	Editorial, Comment